{"id":"sctb14","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SCTB14 works by blocking the interaction between CD47 and SIRPα, which is involved in tumor immune evasion. This blockade leads to the activation of immune cells and enhanced anti-tumor activity.","oneSentence":"SCTB14 is a small molecule targeting the CD47/SIRPα axis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:40.570Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT07362459","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.","status":"RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2025-12-30","conditions":"Non-Small Cell Lung Carcinoma (NSCLC)","enrollment":246},{"nctId":"NCT06304818","phase":"PHASE1, PHASE2","title":"Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.","status":"NOT_YET_RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2024-04-30","conditions":"Advanced Malignant Solid Tumours","enrollment":515}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SCTB14","genericName":"SCTB14","companyName":"Sinocelltech Ltd.","companyId":"sinocelltech-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SCTB14 is a small molecule targeting the CD47/SIRPα axis. Used for Relapsed or refractory multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}